Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
06/10/2026 12:49
BRIEF-Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia Oct 6 (Reuters) - Knight Therapeutics Inc GUD.TO:
KNIGHT THERAPEUTICS - LAUNCHES TAVALISSE IN BRAZIL FOR CHRONIC IMMUNE THROMBOCYTOPENIA
Source text: ID:nGNX39x61Z
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil